NeuroDerm Ltd., a clinical-stage pharmaceutical company, engages in developing products for the treatment of central nervous system (CNS) disorders. The company's product candidates, which have completed Phase IIa clinical trial, include ND0612H for the treatment of patients with severe Parkinson's disease; and ND0612L for the treatment of patients with moderate stage of Parkinson's disease. It is also developing ND0801, which is in Phase IIa clinical trial for the treatment of cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimer's disease, and schizophrenia; and ND0701, an apomorphine-based product candidate for the treatment of moderate to severe Parkinson's disease. NeuroDerm Ltd. was founded in 2003 and is headquartered in Rehovot, Israel.
http://www.priceseries.com/trade/NDRM-NeuroDerm-Ltd-stock-gains-30-percent-a-Trade-Record-by-priceSeries-2017071220170824.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments